Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 286 for your search:
Drug:
rituximab
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
POI-02818
, NIP-02-005, NCT00131313
2.
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
Over 55
Sponsor:
Other
Protocol IDs:
GMALL02
, NCT00198978
3.
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 to 65
Sponsor:
Other
Protocol IDs:
GMALL03
, NCT00199004
4.
Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-Grade Lymphoma in Adults
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
Over 15
Sponsor:
Other
Protocol IDs:
GMALL05
, NCT00199082
5.
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 to 60
Sponsor:
Other
Protocol IDs:
Hemato INCAN 01/2007
, NCT00429065
6.
Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
2006-003750-23
, LINFOTARGAM, NCT00466258
7.
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
HEMOS ALL1105
, NCT00797810
8.
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
152CL201
, NCT00391066
9.
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
NHL 7-2008
, NCT00877214
10.
Phase III Study of Early High-Dose Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Intermediate- or High-Grade Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
15 to 65
Sponsor:
NCI
Protocol IDs:
SWOG-S9704
, CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11
11.
Phase III Randomized Study of Sequential Chemotherapy With or Without Rituximab Followed By Ablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Relapsed, CD20 Positive, Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
CKTO-2000-06
, HOVON-44, HOVON-44/CKVO-2000-06, EU-20042, ISRCTN95614846, NCT00012051
12.
Phase III Randomized Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With Versus Without Rituximab in Elderly Patients With Aggressive Non-Hodgkin's Lymphoma (Randomized portion of the study completed as of 6/2005)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
61 to 80
Sponsor:
Other
Protocol IDs:
DSHNHL-1999-1A
, EU-20243, NCT00052936
13.
Phase III Randomized Study of Salvage Chemotherapy Comprising Dexamethasone, Cisplatin, and Gemcitabine Versus a Standard Platinum-Based Regimen (Dexamethasone, Cisplatin, and High-Dose Cytarabine) Before Autologous Stem Cell Transplantation and With or Without Maintenance Rituximab in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
Other
Protocol IDs:
CAN-NCIC-LY12
, NCT00078949, LY12
14.
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CCBX001-049
, NCT00078598
15.
Gemcitabine, Dexamethasone and Cisplatin Versus Dexamethasone, Cytarabine, Cisplatin in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
7581
, NCT00089817
16.
Phase III Randomized Study of Rituximab Versus Observation Only in Patients With Newly Diagnosed, Previously Untreated, Asymptomatic Stage II-IV Non-Bulky Follicular Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
CRUK-2004-001621-16
, EU-20509, ROCHE-CRUK-001621-16, NCT00112931
17.
Phase III Randomized Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and Rituximab (EPOCH-R) in Patients With Previously Untreated De Novo Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-50303
, ECOG-50303, NCI-05-C-0252, NCT00118209
18.
Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
TROG 99.03
, ALLG NHLLOW5, NCT00115700
19.
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
DSHNHL 2002-1
, NCT00129090
20.
R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-Cell Lymphoma
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
66 to 80
Sponsor:
Other
Protocol IDs:
LNH03-6B
, NCT00144755
21.
Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab in MALT Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
IELSG19
, NCT00210353
22.
Rituximab After Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in Mantle Cell Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
60 and over
Sponsor:
Other
Protocol IDs:
MCL2004-1
, NCT00209209
23.
Efficacy of Rituximab - Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus R-CHOP/R-DHAP in Patients With Untreated Mantle Cell Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
MCL2004-2
, NCT00209222
24.
LMBA02 Protocol for Patients With a Burkitt Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
LMBA02
, NCT00180882
25.
Phase III Randomized Study of Rituximab, Fludarabine, and Cyclophosphamide Versus Observation Only in Patients With High-Risk, Previously Untreated Binet Stage A B-Cell Chronic Lymphocytic Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
GCLLSG-CLL7
, EU-20559, ROCHE-GCLLSG-CLL7, EUDRACT-2005-003-018-14, NCT00275054
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
